Synergistic effects of PF3758309 (PF-309) and oxaliplatin (OXA) in HCT116 cells. (IMAGE)
Caption
(A) Synergy analysis of PF-309 and OXA combination using SynergyFinder software in HCT116 cells. The HSA synergy score of 7.069 indicates a moderate level of synergy.
(B) Determination of optimal concentrations for OXA (3125 nM) and PF-309 (1.53 nM) based on SynergyFinder analysis.
(C) CCK-8 proliferation assay results show the cell viability of HCT116 cells treated with optimal concentrations of OXA, PF-309, and their combination over three days, measured by absorbance at 450 nm. The combination treatment significantly reduced cell proliferation.
(D) Colony formation assay demonstrated that the combination treatment significantly decreased the number of colonies formed in HCT116 cells.
(E) Transwell assay results indicate that the combination of PF-309 and OXA could significantly inhibit the migration and invasion of HCT116 cells.
(F) Effect of PF-309 and OXA combination on CRC organoids. Treatment with PF-309, OXA, or their combination was applied to two CRC organoid models (P01 and P02). The combination treatment significantly reduced organoid size and viability, as indicated by ATP levels, compared with each drug alone. The scale bar represents 100 μm. The data were presented as mean ± standard deviation, with statistical significance indicated (ns, no significance; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001).
Credit
Rongtian Pan, Renrui Zou, Ying Sui, Fei Wu, Dongfeng Wang, Yuan Zhang, Shaorong Yu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND